Acino has made a partnership with the Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences to further expand and strengthen the scope of healthcare services to the patients across the United Arab Emirates.
The Swiss pharmaceutical company has a significant presence in the Middle East and provides both its own pharma business and CDMO services.
"Middle East & Africa is a key market for Acino, this partnership exemplifies our support and dedication to improve the healthcare for patients in UAE, and we look forward to a long and fruitful partnership," said Steffen Saltofte, CEO of Acino.
The Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences and Acino will work together to provide services in medical education, infrastructure development and management in health-related facilities, as well as in areas such as the harnessing of AI in the context of healthcare.
"The Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences plays a key role in the advancement of medicine in the UAE, and we are proud to be able to support the next generation of doctors with opportunities to enrich their knowledge to the benefit of patients," said Dr Andrew Bird, General Manager Acino Middle East & Africa.
Together, both parties have planned a number of joint activities including a series of lectures to local medical undergraduates on topics such as quality assurance and quality control, where Acino is pioneering several technologies and methodologies. Medical students will also have the opportunity to visit Acino's production facilities in Switzerland to better understand the production and quality requirements.
Abdulla Bin Souqat, Executive Director of the Award, added: "This partnership will allow both organisations to make considerable progress in their missions to improve the lives of patients."